AstraZeneca

MedImmune, is a company that produces Synagis, a drug for the prevention of respiratory infections in infants, which accounted for US$ 1.06 billion of its US$ 1.2 billion in revenue for 2005, and FluMist, a nasal spray influenza vaccine introduced in 2004. MedImmune has over 120 drugs in development for conditions including lupus, COPD, asthma, and many types of cancer.

MedImmune

AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Shares in AstraZeneca PLC (LSE:AZN) were the biggest drag on the FTSE 100 on Tuesday, falling over 4.5% on the back of some disappointing results from a trial of a lung cancer drug. Late-stage trial results of the TROPION-Lung01 showed that the overall survival rate from the new drug “did not reach statistical significance,” the company said.

AstraZeneca falls as cancer drug disappoints, analysts cuts FDA approval chances

AstraZeneca shares fell more than 5% Tuesday morning, the biggest one-day drop in seven months, after the British pharmaceutical giant announced disappointing lung cancer drug trial results.

AstraZeneca shares fall 5% on disappointing lung cancer drug trial results

London-listed shares of AstraZeneca fell on Tuesday after results from the company's lung cancer trials showed that its experimental precision drug did not significantly improve overall survival results for patients.

AstraZeneca shares drop as lung cancer drug trial fails to improve survival

Detailed results from one of AstraZeneca's key lung cancer trials released on Monday showed that its experimental precision drug did not significantly improve overall survival results for patients in the trial.

AstraZeneca says lung cancer drug trial shows no significant improvement in overall survival

Innate Pharma SA

MARSEILLE, France--(BUSINESS WIRE)-- #immunotherapy--Regulatory News: Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that AstraZeneca (LSE/STO/Nasdaq: AZN) presented interim results from the randomized NeoCOAST-2 (NCT05061550) Phase 2 platform study during the 2024 World Conference on Lung Cancer on September 8, 2024. The NeoCOAST-2 platform study is intended to assess the safety and efficacy of neoadjuvant durvalumab alone or combined with novel agents and chem.

Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024

Chewy

Chipotle

AstraZeneca's robust pipeline and plentiful growth opportunities make it one of the best healthcare stocks to buy. Chewy is coming off a solid quarter, and there's still more growth ahead in the pet food industry.

3 Market-Beating Stocks to Buy for Less Than $100

Five current and former AstraZeneca (AZN) employees have been detained by police in China in connection with alleged violations of data privacy laws and for importing an unapproved cancer drug, according to a Bloomberg report.

AstraZeneca Employees Held in China for Drug-Import, Data Privacy Investigations

AstraZeneca PLC (LSE:AZN) shares fell 3.5% after it confirmed that five current and former employees in China are being held by police for questioning. The individuals, all Chinese nationals, worked in the company's oncology division marketing cancer treatments, with the police detentions made in the city of Shenzhen earlier this summer.

AstraZeneca slides after confirming five employees held by China police

Some employees of British pharmaceutical giant AstraZeneca have been detained by police in China as part of an investigation, the company confirmed Thursday. "We are aware a small number of our employees in China are under investigation and we have no further information to share at this point," an AstraZeneca spokesperson told CNBC by email.

AstraZeneca says staff detained in China amid reports of a drug-import investigation

AstraZeneca PLC (LSE:AZN) has confirmed that five current and former employees in China are being held by police for questioning. The individuals, all Chinese nationals, worked in the company's oncology division marketing cancer treatments, with the police detentions made in the city of Shenzhen earlier this summer.

AstraZeneca confirms five employees held by China police

The police in China have detained five current and former employees of AstraZeneca for questioning about potential illegal activities, Bloomberg News reported on Thursday, citing people familiar with the matter.

China detains AstraZeneca staff in data, drug-import probes, Bloomberg News reports

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca advances its ambition to revolutionize cancer care with new data across its diverse, industry-leading portfolio and pipeline at the IASLC 2024 World Conference on Lung Cancer (WCLC) hosted by the International Association for the Study of Lung Cancer, September 7 to 10, 2024 and the European Society for Medical Oncology (ESMO) Congress, September 13 to 17, 2024. Across the two meetings, more than 130 abstracts will feature 17 approved and potential.

AstraZeneca advances ambition to improve standards of care in multiple cancer types at WCLC and ESMO 2024

QIAGEN

QGEN's expanded collaboration with AstraZeneca to focus on developing companion diagnostics beyond oncology.

QIAGEN and AstraZeneca Expand Pact to Develop CDx in Chronic Diseases

AstraZeneca (LON: AZN) share price is firing on all cylinders as it sits on its all-time high. It has soared in the last five consecutive weeks, the longest streak since April 2023.

AstraZeneca share price has gone vertical; brace for a pullback

Per third-party reports, AstraZeneca (AZN) has refuted rumors about considering a change in the relocation of a vaccine manufacturing plant from the U.K. to the United States.

AstraZeneca (AZN) Denies Rumors About UK Facility Relocation

British biotech giant AstraZeneca PLC (LSE:AZN) has rebuffed claims that it is moving its vaccine operations to the US. A Financial Times report suggested that AstraZeneca could relocate its vaccine manufacturing operations to Philadelphia due to the Labour government' plans to cut state aid.

Rumours of AstraZeneca relocating vaccine ops to US ‘untrue'

AstraZeneca has warned it could relocate its vaccine manufacturing site from the UK to the U.S. amid a deadlock in negotiations with the Labour government over plans to cut state aid promised to the project, the Financial Times reported on Thursday.

AstraZeneca warns of moving UK vaccine production to US, FT reports

This column is part of the eighth annual Heard on the Street stock picking contest.

AstraZeneca Is a Cancer Leader. Obesity Could Be a Bonus.

GlaxoSmithKline

Johnson & Johnson

Eli Lilly

Merck

Novo Nordisk

Novartis

Pfizer

Roche Holding AG

Sanofi

In the ever-evolving pharmaceutical landscape, financial stability and business resilience are crucial for long-term success. S&P Global, a leading financial information firm, recently released a comprehensive report evaluating the world's top pharmaceutical companies based on their business and financial risk profiles.

Top 10 pharmaceutical companies in 2024: S&P Global's latest ratings and rankings

TOKYO & BASKING RIDGE, N.J.--(BUSINESS WIRE)--ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer.

ENHERTU® Granted Breakthrough Therapy Designation in U.S. for Certain Patients with HER2 Low or HER2 Ultralow Metastatic Breast Cancer

This approval is based on late-stage study data, which shows that treatment with AstraZeneca's (AZN) Imfinzi reduced the risk of recurrence by 32% in certain non-small cell lung cancer patients.

FDA Expands AstraZeneca's (AZN) Imfinzi Label in Lung Cancer

AstraZeneca PLC's (LSE:AZN) blockbuster immunotherapy cancer drug Imfinzi (durvalumab) has received another approval in the US. In combination with chemotherapy, patients suffering resectable early-stage (IIA-IIIB) non-small cell lung cancer (NSCLC) can now receive Imfinzi before and after surgery.

AstraZeneca receives another US approval for cancer drug Imfinzi

The U.S. Food and Drug Administration approved AstraZeneca's blockbuster cancer drug, Imfinzi, for the treatment of patients with a type of non-small cell lung cancer on Thursday.

US FDA approves AstraZeneca's Imfinzi for lung cancer treatment

Diabetes treatments from Merck, Novo Nordisk and AstraZeneca will face the steepest cuts under the IRA, a list showed Thursday.

Medicare Slashes Merck, Novo, AstraZeneca Drug Prices Up To 79% In IRA Negotiations

AstraZeneca's (AZN) Imfinzi plus Lynparza for treating certain patients with primary advanced or recurrent endometrial cancer is approved in the EU based on data from the phase III DUO-E study.

News for AstraZeneca Stock (AZN)